abstract |
The present invention relates to specific dipeptidyl peptidase IV (DPP-IV) inhibitors and specific cannabinoid CB 1 receptor antagonists for the treatment of diabetes, obesity related diabetes, diabetes related disorders, obesity and obesity related disorders It relates to pharmaceutical compositions comprising combinations with inverse agonists, kits containing such combinations and methods of using such compositions. |